Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Cancer Prevention and Treatment》 2010-24
Add to Favorite Get Latest Update

Lapatinib plus adjuvant chemotherapy for metastatic and HER-2 positive advanced breast cancer patients:a meta-analysis

SHEN Jian-jun1,HU Shi-lian1,2,SHEN Gan3,XU Ting-juan2,CHEN Yin2,WU Lei2,XU Wei-ping11.Province Hospital Affiliated of Anhui Medical University,Hefei 230001,P.R.China2.Anhui Evidence-Based Medicine Center,Hefei 230001,P.R.China3.CPC Anhui Provincial Hospital Authorities Cadre Ward,Hefei 230001,P.R.China  
OBJECTIVE:To evaluate the effectiveness and safety of lapatinib on the prognosis of HER-2 positive patients with metastatic and advanced breast cancer by meta-analysis.METHODS:Randomized controlled trials(RCTs) and quasi-RCTs in the following electronic databases:Pubmed,EMBASE,Cochrane library(Issue 2,2010),CBM,CNKI,VIP,and Wanfang data base were searched.All the data were analyzed by Stata 10.0.RESULTS:Four studies involving a total of 1 028 participants met the inclusion criteria.The outcomes of meta-analysis implied that:Compared with adjuvant chemotherapy alone,lapatinib plus adjuvant chemotherapy could improve the time to progression,TTP(HR=0.54,95%CI:0.44-0.66,P0.001) and progession free survival,PFS(HR=0.51,95%CI:0.34-0.76,P=0.001);overall response rate,ORR(RR=1.69,95%CI:1.33-2.14,P0.001);clinical benefit rate,CBR(RR=1.63,95%CI:1.34-1.99,P0.001).There were also statistical differences between the 2 therapies in diarrhea(RR=2.07,95%CI:1.42-3.02,P0.001) and rash(RR=2.31,95%CI:1.64-3.25,P=0.007).CONCLUSIONS:Lapatinib plus adjuvant chemotherapy can improve the time to progression,progression free survival,overall response rate and clinical benefit rate.However,it also elevates the incidence rate of diarrhea and rash.
【CateGory Index】: R737.9
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved